<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488408</url>
  </required_header>
  <id_info>
    <org_study_id>BGBC003</org_study_id>
    <nct_id>NCT02488408</nct_id>
  </id_info>
  <brief_title>Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML</brief_title>
  <official_title>A Phase I Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BerGenBio ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BerGenBio ASA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter open-label study of BGB324 as a single agent and in combination with cytarabine
      in patients with acute myeloid leukemia. BGB324 is a potent selective small molecule
      inhibitor of Axl, a surface membrane protein kinase receptor which is overexpressed in up to
      half of AML cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a dose-escalation and cohort expansion study of BGB324, an Axl kinase
      inhibitor, in patients with acute myeloid leukemia (AML) either as a single agent or in
      combination with cytarabine.

      Study objectives include identifying the maximum tolerated dose (MTD) of BGB324 in AML
      patients who have received previous treatment with cytotoxic chemotherapy (with or without
      haematopoietic stem cell transplantation) or a targeted or biologic agent.

      Identifying the dose limiting toxicity (DLT) profile of BGB324. To explore the safety and
      efficacy of BGB324 and to characterise the pharmacokinetic (PK) profile of BGB324.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BGB324</measure>
    <time_frame>15 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To identify the maximum tolerated dose (MTD) of BGB324 in AML patients who have received previous treatment with cytotoxic chemotherapy (with or without haematopoietic stem cell transplantation) or a targeted or biologic agent and have relapsed after or have been refractory to treatment with such prior therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To identify the safety and tolerability of BGB324 as a single agent (Part B1) and in combination with low dose Cytarabine (Part B2), in patients with AML who are unsuitable for intensive chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB324</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Low dose cytarabine will be administered with BGB324 at a dose selected dose from Part A of the study</description>
    <arm_group_label>Part B</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed written informed consent

          2. Histological or cytological confirmation of AML (with the exception of AML M3).

          3. Age 18 years or older

          4. Female patients of childbearing potential must have a negative serum pregnancy test
             within 3 days prior.

        Additional information in the Protocol.

        Exclusion Criteria:

          1. Patients who have a matched donor and are candidates for allogeneic bone marrow
             transplantation

          2. Pregnant or lactating

          3. Abnormal left ventricular ejection fraction.

          4. History of an ischaemic cardiac event including myocardial infarction within 3 months
             of study entry.

        Additional information in the Protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonja Loges, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf Martinistrasse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Murray Yale, MD, PhD</last_name>
    <phone>47 535 01 564</phone>
    <email>murray.yule@bergenbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonja Loges, MD, PhD</last_name>
    <phone>49 407-410-51969</phone>
    <email>s.loges@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Cortes, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Medizinische Klinik II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Chromik, Dr</last_name>
      <email>joerg.chromik@kgu.de.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf Martinistrasse</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja T Loges, MD, PhD</last_name>
      <phone>49 407-410-51969</phone>
      <email>s.loges@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Heuser, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Tore Gjertsen, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bergenbio.com</url>
    <description>Please see BerGenBio's website for more information.</description>
  </link>
  <reference>
    <citation>Janning M, Ben-Batalla I, Loges S. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy? Expert Rev Hematol. 2015 Apr;8(2):135-8. doi: 10.1586/17474086.2015.997704.</citation>
    <PMID>25578023</PMID>
  </reference>
  <reference>
    <citation>Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013 Oct 3;122(14):2443-52. doi: 10.1182/blood-2013-03-491431.</citation>
    <PMID>23982172</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 15, 2016</lastchanged_date>
  <firstreceived_date>April 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
